文献速递药物不良反应与药物警戒

药物警戒中比较器的准定量偏倚分析

Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis.
PubMed 文献 · Drug Saf · 2024-05-04

基于FDA不良事件报告系统,选取利伐沙班-肝毒性与卡格列净-急性肾损伤两个药物事件组合,采用三种不成比例分析指标,比较无限制、活性对照及活性对照加类别排除三种比较器策略,并在两个日历时间段内评估偏倚方向性,未发现比较器选择的一致可预测模式。

要点

  • 不同比较器对不成比例分析偏倚方向无一致可预测模式。
  • 基于外部事件的日历时间限制对偏倚方向影响显著。
  • 利伐沙班-肝毒性组合在任何比较器下均无假阳性信号。

核心结论

  • 无法确定特定比较器对不成比例分析估计偏倚方向的一致且可预测的模式。
  • 基于相关外部事件的日历时间限制对偏倚方向有相当大的影响。

研究设计与样本

  • 基于美国FDA不良事件报告系统的准定量偏倚分析,聚焦两个具有刺激报告倾向的药物事件组合:利伐沙班与肝毒性、卡格列净与急性肾损伤。
  • 评估三种不成比例分析估计(报告比值比、比例报告比、信息成分)在无限制比较器(全数据)、活性比较器、活性比较器加类别排除下的偏倚方向性。
  • 分析在两个日历时间段内进行,时间段基于外部事件(直接口服抗凝药获批、FDA关于SGLT2抑制剂急性肾损伤的安全警告)定义。

主要发现

  • 利伐沙班与肝毒性组合无论使用何种比较器均未出现假阳性信号。
  • 限制在初始获批后时期导致假阳性信号,且限制性比较器表现更差。
  • 卡格列净与急性肾损伤组合出现假阳性信号,限制性比较器表现更好。
  • 限制在FDA警告前时期削弱了卡格列净与急性肾损伤的假阳性信号,跨比较器一致。

临床怎么用

  • 药物警戒不成比例分析中比较器选择需结合具体药物事件组合与日历时间背景,不宜默认统一策略。
  • 基于外部事件的日历时间限制应作为偏倚控制的重要考虑因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: It is unclear which comparator is the most appropriate for bias reduction in disproportionality analyses based on spontaneous reports. We conducted a quasi-quantitative bias analysis using two well-studied drug-event combinations to assess how different comparators influence the directionality of bias in pharmacovigilance. METHODS: We used the US Food and Drug Administration Adverse Event Reporting System focusing on two drug-event combinations with a propensity for stimulated reporting: rivaroxaban and hepatotoxicity, and canagliflozin and acute kidney injury. We assessed the directionality of three disproportionality analysis estimates (reporting odds ratio, proportional reporting ratio, information component) using one unrestricted comparator (full data) and two restricted comparators (active comparator, active comparator with class exclusion). Analyses were conducted within two calendar time periods, defined based on external events (approval of direct oral anticoagulants, Food and Drug Administration safety warning on acute kidney injury with sodium-glucose cotransporter 2 inhibitors) hypothesized to alter reporting rates. RESULTS: There were no false-positive signals for rivaroxaban and hepatotoxicity irrespective of the comparator. Restricting to the initial post-approval period led to false-positive signals, with restricted comparators performing worse. There were false-positive signals for canagliflozin and acute kidney injury, with restricted comparators performing better. Restricting to the period before the Food and Drug Administration warning weakened the false-positive signal for canagliflozin and acute kidney injury across comparators. CONCLUSIONS: We could not identify a consistent and predictable pattern to the directionality of disproportionality analysis estimates with specific comparators. Calendar time-based restrictions anchored on relevant external events had a considerable impact.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Gravel CA, Bai W, Douros A, et al. Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis. Drug Saf. 2024. PMID: 38703312. doi:10.1007/s40264-024-01433-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。